Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Campus Benjamin Franklin, Berlin, Germany.
Berlin Institute of Health, Berlin, Germany.
Crit Care Med. 2024 Mar 1;52(3):464-474. doi: 10.1097/CCM.0000000000006157. Epub 2024 Jan 5.
Extracorporeal cardiopulmonary resuscitation (ECPR) is the implementation of venoarterial extracorporeal membrane oxygenation (VA-ECMO) during refractory cardiac arrest. The role of left-ventricular (LV) unloading with Impella in addition to VA-ECMO ("ECMELLA") remains unclear during ECPR. This is the first systematic review and meta-analysis to characterize patients with ECPR receiving LV unloading and to compare in-hospital mortality between ECMELLA and VA-ECMO during ECPR.
Medline, Cochrane Central Register of Controlled Trials, Embase, and abstract websites of the three largest cardiology societies (American Heart Association, American College of Cardiology, and European Society of Cardiology).
Observational studies with adult patients with refractory cardiac arrest receiving ECPR with ECMELLA or VA-ECMO until July 2023 according to the Preferred Reported Items for Systematic Reviews and Meta-Analysis checklist.
Patient and treatment characteristics and in-hospital mortality from 13 study records at 32 hospitals with a total of 1014 ECPR patients. Odds ratios (ORs) and 95% CI were computed with the Mantel-Haenszel test using a random-effects model.
Seven hundred sixty-two patients (75.1%) received VA-ECMO and 252 (24.9%) ECMELLA. Compared with VA-ECMO, the ECMELLA group was comprised of more patients with initial shockable electrocardiogram rhythms (58.6% vs. 49.3%), acute myocardial infarctions (79.7% vs. 51.5%), and percutaneous coronary interventions (79.0% vs. 47.5%). VA-ECMO alone was more frequently used in pulmonary embolism (9.5% vs. 0.7%). Age, rate of out-of-hospital cardiac arrest, and low-flow times were similar between both groups. ECMELLA support was associated with reduced odds of mortality (OR, 0.53 [95% CI, 0.30-0.91]) and higher odds of good neurologic outcome (OR, 2.22 [95% CI, 1.17-4.22]) compared with VA-ECMO support alone. ECMELLA therapy was associated with numerically increased but not significantly higher complication rates. Primary results remained robust in multiple sensitivity analyses.
ECMELLA support was predominantly used in patients with acute myocardial infarction and VA-ECMO for pulmonary embolism. ECMELLA support during ECPR might be associated with improved survival and neurologic outcome despite higher complication rates. However, indications and frequency of ECMELLA support varied strongly between institutions. Further scientific evidence is urgently required to elaborate standardized guidelines for the use of LV unloading during ECPR.
体外心肺复苏(ECPR)是在难治性心脏骤停期间实施静脉动脉体外膜肺氧合(VA-ECMO)。在 ECPR 期间,Impella 辅助左心室(LV)卸载与 VA-ECMO 联合使用(“ECMELLA”)的作用仍不清楚。这是第一项对接受 LV 卸载的 ECPR 患者进行特征描述并比较 ECMELLA 和 VA-ECMO 在 ECPR 期间院内死亡率的系统评价和荟萃分析。
根据 Preferred Reported Items for Systematic Reviews and Meta-Analysis 清单,检索了 Medline、Cochrane 对照试验中心注册库、Embase 和三个最大的心脏病学会(美国心脏协会、美国心脏病学会和欧洲心脏病学会)的摘要网站。
纳入了直至 2023 年 7 月接受 ECPR 治疗的难治性心脏骤停成年患者的观察性研究,这些患者接受了 ECMELLA 或 VA-ECMO 治疗。从 32 家医院的 13 份研究记录中提取患者和治疗特征以及院内死亡率,这些医院共纳入了 1014 例 ECPR 患者。使用随机效应模型的 Mantel-Haenszel 检验计算比值比(OR)和 95%置信区间。
762 例患者(75.1%)接受了 VA-ECMO 治疗,252 例(24.9%)接受了 ECMELLA 治疗。与 VA-ECMO 相比,ECMELLA 组初始可电击心电图节律(58.6% vs. 49.3%)、急性心肌梗死(79.7% vs. 51.5%)和经皮冠状动脉介入治疗(79.0% vs. 47.5%)的患者更多。VA-ECMO 更常单独用于肺栓塞(9.5% vs. 0.7%)。两组的年龄、院外心脏骤停发生率和低血流时间相似。与单独使用 VA-ECMO 相比,ECMELLA 支持与死亡率降低的几率相关(OR,0.53 [95%CI,0.30-0.91]),与良好神经功能结局的几率增加相关(OR,2.22 [95%CI,1.17-4.22])。ECMELLA 治疗与数值上增加但无统计学意义的更高并发症发生率相关。主要结果在多项敏感性分析中仍然稳健。
ECMELLA 支持主要用于急性心肌梗死患者和 VA-ECMO 治疗肺栓塞。在 ECPR 期间使用 ECMELLA 支持可能与生存率和神经功能结局改善相关,尽管并发症发生率更高。然而,ECMELLA 支持的适应证和频率在各机构之间差异很大。迫切需要进一步的科学证据来制定 ECPR 期间 LV 卸载使用的标准化指南。